Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

Buy Bank of America Stock for What It Is

By Chris Markoch, InvestorPlace Contributor

Bank of America stock offers upside potential but you’re probably not going to get rich with this investment.

Chipotle Stock Is Ready to Take Your Order

By Chris Markoch, InvestorPlace Contributor

For years, Chipotle stock appeared in danger of crumbling. But with a remarkable recovery from its scandals, the fast-casual eatery can focus on its growth strategies with a clean slate.

Is the Reward of Buying General Electric Worth the Risk?

By Chris Markoch, InvestorPlace Contributor

GE offers a possible case for upside if you’re a careful contrarian. However, keep in mind that the company still struggles against many risk factors.

Hexo Stock Is in a Race Against Time

By Chris Markoch, InvestorPlace Contributor

Hexo stock has fallen just over 80% as it waits for Cannabis 2.0 to take root. However, after a year of overpromising, investors' patience is thin.

Aphria Stock Has Work to Do to Maintain the Trust of Investors

By Chris Markoch, InvestorPlace Contributor

Aphria stock has risen above other cannabis investments for good reason. But APHA also has some of the same credibility issues that plague its rivals.

Load More